RELATIVITY-047
Proved that adding a LAG-3 blocker to PD-1 blockade delays progression, with far less toxicity than the ipilimumab combination.
PFS 10.1 vs 4.6 months (HR 0.75) led to FDA approval of Opdualag in March 2022. OS was not formally significant at first analysis; extended follow-up reported median OS 51.0 vs 34.1 months with 3-year OS 54.6% vs 48.0% (JCO 2024) and a 4-year update (EJC 2025) with the upper confidence bound below 1. Grade 3-4 treatment-related events ~21% versus ~59% for nivolumab-ipilimumab in CheckMate 067.
- Median 10.1 vs 4.6 months with Nivolumab + relatlimab compared with Nivolumab; about 5.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 25 percent lower chance of the event at any given time (hazard ratio 0.75).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 54.6 vs 48 out of 100 alive at 3 years with Nivolumab + relatlimab compared with Nivolumab; 6.6 more per 100.
- Roughly one extra person helped for every 15 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Untreated unresectable or metastatic melanoma: nivolumab + relatlimab (fixed dose) vs nivolumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
714 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Nivolumab + relatlimab | — | 10.1 months | 0.75 | — | link |
| Nivolumab | — | 4.6 months | ||||
| Overall survival (3-year) | Nivolumab + relatlimab | — | 54.6% | — | — | link |
| Nivolumab | — | 48% |
Pages like this
not linked directly; found by shared links- TrialRELATIVITY-098
Shares Caution: LAG-3 blockade outside active disease, Relatlimab + nivolumab, LAG-3, Nivolumab.
- ProductFianlimab
Shares Caution: LAG-3 blockade outside active disease, Fianlimab + cemiplimab phase 3 (first-line melanoma), LAG-3, Melanoma.
- Key paperRELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma
Shares CheckMate 067, Relatlimab + nivolumab, LAG-3, Nivolumab.
- InstitutionIstituto Nazionale Tumori IRCCS Fondazione G. Pascale
Shares CheckMate 067, Relatlimab + nivolumab, LAG-3, Nivolumab.
- PersonF. Stephen Hodi
Shares CheckMate 067, CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later, Nivolumab, PD-1.
- PersonJames Larkin
Shares CheckMate 067, CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later, Nivolumab, Melanoma.
- Key paperCheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma
Shares CheckMate 067, Relatlimab + nivolumab, Nivolumab, PD-1.
- InstitutionUPMC Hillman Cancer Center
Shares Relatlimab + nivolumab, LAG-3, Melanoma.